Sugi Predict

Sugi Predict / Compounds / SCHEMBL2018258

SCHEMBL2018258

SCHEMBL2018258

CC(C)C(C)(c1ccccn1)C(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ CHRM2 P08172 1/20 0.39
▸ CYP1A2 P05177 3/20 0.37
▸ BLM P54132 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CCR1 P32246 1/20 0.37
▸ CCR5 P51681 1/20 0.37
▸ CCR8 P51685 1/20 0.37
▸ METAP1 P53582 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ DOHH Q9BU89 1/20 0.37
▸ P4HTM Q9NXG6 1/20 0.37
▸ TDP1 Q9NUW8 3/20 0.36
▸ SLC22A2 O15244 1/20 0.36
▸ SLC22A1 O15245 1/20 0.36
▸ PGR P06401 1/20 0.36
▸ THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5839742 0.88 SMN1; SMN2 (0.44) SMN1; SMN2L3MBTL1CHRM2CYP1A2BLM
SCHEMBL20809866 0.83 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1CHRM2CYP1A2BLM
SCHEMBL22863374 0.83 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1CHRM2CYP1A2BLM
SCHEMBL26833409 0.79 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1CHRM2CYP1A2BLM
SCHEMBL12862746 0.79 SMN1; SMN2 (0.47) SMN1; SMN2L3MBTL1CHRM2CYP1A2BLM
SCHEMBL16132386 0.79 SMN1; SMN2 (0.47) SMN1; SMN2L3MBTL1CHRM2CYP1A2BLM
SCHEMBL26833410 0.79 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1CHRM2CYP1A2BLM
SCHEMBL21742287 0.79 SMN1; SMN2 (0.47) SMN1; SMN2L3MBTL1CHRM2CYP1A2BLM
SCHEMBL12238622 0.79 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1CHRM2CYP1A2BLM
SCHEMBL5838893 0.78 SMN1; SMN2 (0.35) SMN1; SMN2L3MBTL1KDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4384226-A2 DIPHOSPHINE COMPOUNDS AND COMPLEXES Cancer Research Technology Limited (GB) 2024-06-19 — — EP claimed
WO-2023017101-A2 DIPHOSPHINE COMPOUNDS AND COMPLEXES CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-02-16 — — WO claimed
EP-4028020-A1 ANTIVIRAL PRODRUGS AND FORMULATIONS THEREOF The Scripps Research Institute (US) 2022-07-20 — — EP disclosed
WO-2021050961-A1 ANTIVIRAL PRODRUGS AND FORMULATIONS THEREOF THE SCRIPPS RESEARCH INSTITUTE (US) 2021-03-18 — — WO disclosed
WO-2018049015-A1 COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PD-1 ANTAGONISTS TRUSTEES OF TUFTS COLLEGE (US) 2018-03-15 — — WO disclosed
EP-3265448-A1 RILUZOLE PRODRUGS AND THEIR USE Biohaven Pharmaceutical Holding Company Ltd. (US) 2018-01-10 — — EP disclosed
WO-2016140879-A9 RILUZOLE PRODRUGS AND THEIR USE BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) 2016-11-03 — — WO disclosed
US-20140213532-A1 COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES KAI PHARMACEUTICALS, INC. (US) 2014-07-31 — — US disclosed
US-20120329829-A1 Dopamine Transporter Inhibitors for Use in Treatment of Movement Disorders and Other CNS Indications PREXA PHARMACEUTICALS, INC. (US) 2012-12-27 — — US disclosed
US-8258305-B2 Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications PREXA PHARMACEUTICALS, INC. (US) 2012-09-04 — — US disclosed
EP-2338881-A1 Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications Prexa Pharmaceuticals, Inc. (US) 2011-06-29 — — EP disclosed
US-6300340-B1 USEFUL FOR THERAPY OF CANCER AND SOLID TUMORS ADIR ET COMPAGNIE (FR) 2001-10-09 — — US disclosed
EP-1074543-A1 AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS MEIJI SEIKA KAISHA LTD. (JP) 2001-02-07 — — EP disclosed
EP-1036061-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2000-09-20 — — EP disclosed
WO-1999029664-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 1999-06-17 — — WO disclosed
US-5869696-A OLIGONUCLEOTIDE CLEAVING REAGENT CONSISTING OF AQUEOUS SOLUTION OF METHYLAMINE AND AQUEOUS SOLUTION OF DIMETHYLAMINE OR TRIMETHYLAMINE BECKMAN INSTRUMENTS, INC. (US) 1999-02-09 — — US disclosed
US-5516797-A SUPPRESSING GRAFT REJECTION VERTEX PHARMACEUTICALS, INCORPORATED (US) 1996-05-14 — — US disclosed
EP-0659181-A1 SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1995-06-28 — — EP disclosed
US-5296572-A Mixing unsaturated or alkenoylamine with dimethylacrylamide, crosslinker, water, adding emulsifier, adding organic phase, agitating, adding initiator, adjusting pH, adding promoter, polymerizing, isolating polyamide beads Sparrow, James (US) 1994-03-22 — — US disclosed
WO-1994005639-A1 SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1994-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329829-A1 Dopamine Transporter Inhibitors for Use in Treatment of Movement Disorders and Other CNS Indications SLC6A3, SLC6A2, SLC18A2 SMN1; SMN2 318/4885L3MBTL1 2365/4885CHRM2 908/4885
US-20140213532-A1 COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES ADM2, SLC7A1, ARG1 SMN1; SMN2 1974/4885L3MBTL1 3758/4885CHRM2 1685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.